

## CORRESPONDENCE OPEN



## Clinical Research

## Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?

© The Author(s) 2022

*Prostate Cancer and Prostatic Diseases*; <https://doi.org/10.1038/s41391-022-00617-3>

## TO THE EDITOR:

Ah-Thiane and Supiot [1] commented on our recent publication about the SPARE-trial [2] and we are grateful for the fruitful comments.

The CARLHA trial, published by Supiot et al. [3], was undoubtedly the first trial to evaluate the effect of abiraterone (AA) alone in patients with biochemically-relapsing prostate cancer patients. Comparable to the LACOG-0415 trial, the CARLHA trial was conducted in the setting of castration-naïve patients revealing that treatment with AA alone does not achieve castrate levels of testosterone in every patient. However, both trials recruited patients in a disease state that should be clearly distinguished from the SPARE-trial, which was undertaken in castration-resistant prostate cancer (CRPC) patients. Any result from the CARLHA, LACOG-0415 and the SPARE trial should be interpreted with caution in view of this important difference. This difference may account for the seemingly contradicting results regarding serum-testosterone levels measured under treatment in the trials. These results should not be regarded as conflicting but should prompt us to further evaluate the different disease states with regard to the efficacy of AA on steroidogenesis and mechanisms of resistance.

The elevated serum levels of LH and FSH measured in the SPARE-trial, similar to the results in the CARLHA trial, may impair the efficacy of AA and display an unpredictable hazard to patients receiving AA without ADT - leading to early progression, and consequently shortened cancer-specific and overall survival as outlined in the SPARE-protocol [4].

However, LH acts mainly on prostate cancer cells by causing an increase in the expression of several key steroidogenic enzymes including CYP11A1, CYP17A1 and CYP19A1 [5]. Silencing the LH receptor suppresses androgen synthesis [6]. We therefore conclude that the constant low levels of serum testosterone < 0.029 ng/ml in the SPARE trial demonstrate that the steroidogenic potential of LH may not be clinically relevant in CRPC patients treated with AA alone. Even though FSH may drive transition of prostate-cancer cells to castration-resistance in an androgen-independent manner, its role in CRPC cells is a matter of debate. In view of the exploratory results of the SPARE-trial showing no difference in radiographic-progression

free survival at 12 months the effect of elevated serum LH and FSH levels noticed may also be of minor clinical importance.

With regard to efficacy and toxicity, the exploratory SPARE trial was not powered to show any difference in any of the endpoints analyzed. Quality of life was not evaluated due to lack of power, whereas analysis of toxicity was mandatory by health care authorities but failed to show any difference.

In summary, as clearly stated in the conclusions, the exploratory results of the SPARE trial warrant further confirmatory trials to demonstrate the efficacy of AA treatment without continuous LHRH-therapy in mCRPC patients. The results of the CARLHA and the LACOG-0415 trial display comparable drawbacks and limitations being phase-I and II trials lacking statistical power. However, all three trials were driven by the same vision of identifying ADT-free treatment options for prostate cancer patients, which is a desirable aim due to toxicity and costs of ADT.

Carsten-Henning Ohlmann <sup>1,2</sup> ✉

<sup>1</sup>Johanniter Kliniken Bonn, Johanniterstr. 3-5, 53113 Bonn, Germany.

<sup>2</sup>Department of Urology and Pediatric Urology, Saarland University, Kirrberger Street 100, 66421 Homburg/Saar, Germany.

✉email: carsten.ohlmann@bn.johanniter-kliniken.de

## REFERENCES

- Ah-Thiane L and Supiot S Should LHRH therapy be continued in patients receiving Abiraterone Acetate. *Prostate Cancer Prostatic Dis.* 2022. <https://doi.org/10.1038/s41391-022-00584-9>.
- Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. *Prostate Cancer Prostatic Dis.* 2022. <https://doi.org/10.1038/s41391-022-00533-6>.
- Supiot S, Campion L, Pommier P, Dore M, Palpacuer C, Racadot S, et al. Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LHRH agonists (CARLHAGEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP. *Oncotarget.* 2018;9:22147–57. <https://doi.org/10.18632/oncotarget.25189>
- Ohlmann C-H, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. *Trials.* 2017;18:457.
- Stroomberg HV, Jørgensen A, Brasso K, Nielsen JE, Juul A, Frederiksen H, et al. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients. *PLoS One.* 2020;15:e0238814. <https://doi.org/10.1371/journal.pone.0238814>.
- Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, et al. Effects of luteinizing hormone receptor signaling in prostate cancer cells. *Prostate.* 2015;75:141–50. <https://doi.org/10.1002/pros.22899>.

Received: 22 August 2022 Revised: 7 November 2022 Accepted: 7 November 2022

Published online: 29 November 2022

## AUTHOR CONTRIBUTIONS

CHO: Manuscript preparation, Manuscript editing and review.

## FUNDING

Open Access funding enabled and organized by Projekt DEAL.

## COMPETING INTERESTS

The author declares no conflicts of interests other than the financial support of the SPARE-trial by Janssen-Cilag GmbH, Germany.

## ADDITIONAL INFORMATION

**Correspondence** and requests for materials should be addressed to Carsten-Henning Ohlmann.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022